Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New and Emerging Treatments
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: December 15, 2020 Expiration: December 14, 2021
Start Activity
Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by an educational grant from
Merck
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Javed Butler, MD, MPH, MBA

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize new data from PIONEER-HF regarding timing of initiation of patients receiving ARNIs who have experienced acute decompensated HF
  • Describe the expected benefits on SGLT2 inhibitors in patients with HF
  • Summarize clinical trial data regarding investigational treatments for patients with HFrEF

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director, Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, has received funds for research support from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, and The Medicines Company.
Javed Butler, MD, MPH, MBA

Patrick H. Lehan Chair in Cardiovascular Research
Professor and Chairman
, Department of Medicine
Professor of Physiology
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Javed Butler, MD, MPH, MBA, has disclosed that he has received consulting fees from Abbott, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Sequana Medical, V-Wave Limited, and Vifor and fees for non-CME/CE services from AstraZeneca, Boehringer Ingelheim/Lilly, Janssen, and Novartis.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for cardiologists, hospitalists, internists, and other healthcare providers who treat patients with heart failure.

Goal

The goal of this program is to improve the knowledge and competence of cardiologists, internists, hospitalists, and other clinicians on new and emerging treatment strategies to reduce HF-related hospitalization and death.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 15, 2020, through December 14, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

New and Emerging Treatments
  • CME

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Javed Butler, MD, MPH, MBA
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: December 15, 2020 Expiration: December 14, 2021

This program is divided into several short segments which you can step through using the Video Chapters menu.
PreviousNext

Related Content

Expert video from Clinical Care Options (CCO) on optimal prevention and management of CV morbidities in settings of heart failure, diabetes, and CKD

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Javed Butler, MD, MPH, MBA Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2020 Expired: December 14, 2021

CCO slides from Deepak Bhatt, Javed Butler: Latest on SGLT2 inhibitors in HF, emerging therapies in HFrEF, timing of ARNI initiation in decompensated HF, and more.

Released: December 9, 2020

Expert commentary on key highlights in heart failure from AHA 2020, provided by Clinical Care Options

Javed Butler, MD, MPH, MBA Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: December 9, 2020 Expired: December 8, 2021

High-dose trivalent influenza vaccine comparable to standard-dose quadrivalent vaccine in deaths or cardiopulmonary hospitalizations in high-risk CV disease; AHA results reported by CCO

Released: November 20, 2020

Video Chapters


Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by an educational grant from
Merck

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue